Anti-LeY monoclonal antibody (mAb) hu3S193 as consolidation therapy for patients (pts) with relapsing platinum sensitive ovarian cancer (OC) after achieving a second complete response (2CR).

Files in this item

Files Size Format View

There are no files associated with this item.

This item appears in the following Collection(s)

Search DSpace


My Account